Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6863MR)

This product GTTS-WQ6863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3687MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ15040MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ192MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ5938MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ865MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ8106MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ6601MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ7462MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW